[Seoul = News Desk] As the domestic stock market broke free from the previous day's shock plunge and demonstrated a powerful rebound, bio and pharmaceutical stocks simultaneously showed an upward trend, drawing investors' attention. In particular, a buy-side circuit breaker was triggered in the KOSPI market, indicating a rapid recovery in investment sentiment toward risk assets.

As of the morning session on the 9th, HLB traded at 50,900 won, up 5.38% from the previous trading day, confirming strong buying momentum. It also recorded an intraday high of 51,600 won. HLB's upward trend spread throughout the group's affiliates, leading to a combined increase of 5.88% for HLB Life Sciences, 5.76% for HLB Global, 3.43% for HLB Pharm, and 3.85% for HLB Innovation.

The rebound of leading bio stocks is also noticeable. Alteogen recorded a surge of 12.95% to reach 327,000 won, while Celltrion rose by 5.96% and Samsung Biologics increased by 2.90%. In addition, ABL Bio (8.24%), Olix (8.82%), Peptro (6.51%), and HK inno.N (6.92%) also climbed, driving a rally across the overall bio sector.

The sharp rebound in the domestic stock market on this day is the result of eased fear following the previous day's global market plunge and a massive inflow of bargain hunting. As the price of KOSPI 200 futures skyrocketed, the Korea Exchange triggered a buy-side circuit breaker, which rapidly improved overall market investment sentiment.

The market analyzes that the recent rebound in the U.S. stock market has reignited risk appetite, leading to a concentration of buying in the bio sector, which has strong growth stock characteristics. In particular, there are forecasts that if expectations of interest rate cuts are maintained, the appeal of the bio sector will be highlighted once again.

Positive factors for individual stocks also support the upward trend. HLB reflected expectations for its anticancer drug business and the progress of global clinical trials, while Alteogen saw a reassessment of its technology export potential and platform technology competitiveness. Expectations for continued benefits from the growth of the global bio market remain intact for Celltrion and Samsung Biologics.

The securities industry evaluates that the bio sector has entered a rebound phase after undergoing a recent correction. However, they advised that investors need a selective approach, as volatility for individual stocks could expand depending on global monetary policies, clinical trial results, and the progress of technology exports.

[This article was written based on publicly available market data and official materials, and artificial intelligence (AI) was utilized in the process of drafting the article and organizing the information. The information provided in this article is for general informational purposes and does not constitute a recommendation to invest in any specific stock or financial product. Investing in the stock and financial markets carries the risk of principal loss, and all responsibility for investment decisions lies solely with the investor. Please be sure to review related disclosures and official materials before making an investment decision. This publication bears no legal or financial responsibility for the provided information.]